Company research
Tourmaline Bio, Inc.
CIK 1827506Updated Sep 27, 2026
Securities
Historical securities (1)
TRML · NASDAQ · equity · closed Oct 27, 2025Name history
Talaris Therapeutics, Inc. · through Oct 18, 2023
TRML price & chart
Historical security
This listing closed Oct 27, 2025. Live provider charts are shown only for current listings.
About the company
Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that establish new standards of care for patients with life-altering inflammatory and immune diseases. Tourmaline’s lead asset is pacibekitug. For more information about Tourmaline and pacibekitug, please visit https://www.tourmalinebio.com or follow us on LinkedIn, X or Bluesky.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 309,001,000Source | 210,295,000Source | 193,715,000Source | 251,422,000Source |
| Property, Plant and Equipment, NetUSD | 55,000Source | 85,000Source | 5,348,000Source | 4,804,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 30,506,000Source | 140,726,000Source | 13,670,000Source | 18,614,000Source |
| Assets, CurrentUSD | 268,842,000Source | 208,874,000Source | 185,613,000Source | 246,514,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 10,539,000Source | 5,923,000Source | 4,331,000Source | 2,543,000Source |
| Operating Lease, Right-of-Use AssetUSD | 212,000Source | 362,000Source | 2,643,000Source | — |
| Other Assets, NoncurrentUSD | 3,032,000Source | 747,000Source | 111,000Source | 104,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 8,949,000Source | 5,253,000Source | 13,660,000Source | 8,613,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | — | — |
| Common Stock, Value, IssuedUSD | 3,000Source | 2,000Source | 4,000Source | 4,000Source |
| Additional Paid in CapitalUSD | 435,014,000Source | 267,024,000Source | — | — |
| Retained Earnings (Accumulated Deficit)USD | -135,261,000Source | -62,051,000Source | -164,741,000Source | -90,847,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 296,000Source | 67,000Source | -721,000Source | -78,000Source |
| Stockholders' Equity Attributable to ParentUSD | 300,052,000Source | 205,042,000Source | 180,055,000Source | 242,809,000Source |
| Additional Paid in Capital, Common StockUSD | — | — | 345,513,000Source | 333,730,000Source |
| Liabilities and EquityUSD | 309,001,000Source | 210,295,000Source | 193,715,000Source | 251,422,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 8,909,000Source | 5,002,000Source | 11,462,000Source | 7,987,000Source |
| Operating Lease, Liability, CurrentUSD | 227,000Source | 221,000Source | 910,000Source | — |
| Accounts Payable, CurrentUSD | 3,583,000Source | 1,071,000Source | 3,887,000Source | 2,556,000Source |
| Operating Lease, Liability, NoncurrentUSD | 17,000Source | 194,000Source | 1,974,000Source | — |
| Other Liabilities, NoncurrentUSD | 23,000Source | 57,000Source | 16,000Source | 33,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 5,099,000Source | 3,710,000Source | 6,665,000Source | 5,431,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 251,121,000Source | 203,000,000Source | — | — |
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | — | — |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -73,894,000Source | -47,833,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | — | 1,383,000Source | 623,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 6,593,000Source | 5,769,000Source | 11,156,000Source | 3,778,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 2,437,000Source | -44,000Source | 1,664,000Source | 1,323,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -77,263,000Source | -28,081,000Source | -60,857,000Source | -39,988,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -194,305,000Source | 3,840,000Source | 55,671,000Source | -96,387,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 9,000Source | 56,000Source | 3,043,000Source | 2,437,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 4,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 161,348,000Source | 156,720,000Source | 242,000Source | 137,400,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -110,220,000Source | 132,479,000Source | -4,944,000Source | 1,025,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 30,733,000Source | 140,953,000Source | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 6,593,000Source | 5,769,000Source | 11,156,000Source | 3,778,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 251,121,000Source | 203,000,000Source | — | — |
| DepreciationUSD | 39,000Source | 33,000Source | 1,400,000Source | 600,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | 33,000Source |
| General and Administrative ExpenseUSD | 22,747,000Source | 13,041,000Source | 19,472,000Source | 13,262,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 0Source | — | — | — |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | -643,000Source | -65,000Source |
| Net Income (Loss) Attributable to ParentUSD | -73,210,000Source | -42,124,000Source | -73,894,000Source | -47,833,000Source |
| Operating ExpensesUSD | 89,732,000Source | 45,409,000Source | 76,477,000Source | 47,507,000Source |
| Operating Lease, ExpenseUSD | — | — | 1,000,000Source | 700,000Source |
| Other Nonoperating Income (Expense)USD | 16,522,000Source | 3,285,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | 139,523,000Source |
| Proceeds from Stock Options ExercisedUSD | 0Source | 144,000Source | 108,000Source | 317,000Source |
| Realized Investment Gains (Losses)USD | 87,000Source | 17,000Source | — | — |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -89,732,000Source | -45,409,000Source | -76,477,000Source | -47,507,000Source |
| Other Nonoperating Income (Expense)USD | 16,522,000Source | 3,285,000Source | — | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -73,210,000Source | -42,124,000Source | -73,894,000Source | -47,833,000Source |
| Earnings Per Share, BasicUSD per share | -2.89Source | -8.87Source | -1.79Source | — |
| Earnings Per Share, DilutedUSD per share | -2.89Source | -8.87Source | -1.79Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 25,348,000Source | 4,747,000Source | 41,248,392Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 25,348,000Source | 4,747,000Source | 41,248,392Source | — |
| Interest Expense (non-operating)USD | 0Source | — | — | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 22,747,000Source | 13,041,000Source | 19,472,000Source | 13,262,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | 5,700,000Source | — | 2,583,000Source | -326,000Source |
| Operating ExpensesUSD | 89,732,000Source | 45,409,000Source | 76,477,000Source | 47,507,000Source |
| Operating Lease, ExpenseUSD | — | — | 1,000,000Source | 700,000Source |
| Realized Investment Gains (Losses)USD | 87,000Source | 17,000Source | — | — |
| Research and Development ExpenseUSD | 66,985,000Source | 32,368,000Source | 57,005,000Source | 34,245,000Source |
Filing attachments
d80074dex991.htm · 8-K · 2025-09-09
EX-99.1 3 d80074dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG - Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion - - Transaction reflects the potential of Tourmaline’s pacibekitug, a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential, for the treatment of cardiovascular diseases - - Transaction is expected to be completed in…
Read attachment ↗